Crystallisation Behaviour of Pharmaceutical Compounds Confined within Mesoporous Silicon

The poor aqueous solubility of new and existing drug compounds represents a significant challenge in pharmaceutical development, with numerous strategies currently being pursued to address this issue. Amorphous solids lack the repeating array of atoms in the structure and present greater free energy...

Full description

Bibliographic Details
Main Authors: Eleanor C. L. Jones, Luis M. Bimbo
Format: Article
Language:English
Published: MDPI AG 2020-03-01
Series:Pharmaceutics
Subjects:
Online Access:https://www.mdpi.com/1999-4923/12/3/214
id doaj-57f122e64fc546438669e2886b89583c
record_format Article
spelling doaj-57f122e64fc546438669e2886b89583c2020-11-25T02:24:32ZengMDPI AGPharmaceutics1999-49232020-03-0112321410.3390/pharmaceutics12030214pharmaceutics12030214Crystallisation Behaviour of Pharmaceutical Compounds Confined within Mesoporous SiliconEleanor C. L. Jones0Luis M. Bimbo1Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow G4 0RE, UKStrathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow G4 0RE, UKThe poor aqueous solubility of new and existing drug compounds represents a significant challenge in pharmaceutical development, with numerous strategies currently being pursued to address this issue. Amorphous solids lack the repeating array of atoms in the structure and present greater free energy than their crystalline counterparts, which in turn enhances the solubility of the compound. The loading of drug compounds into porous materials has been described as a promising approach for the stabilisation of the amorphous state but is dependent on many factors, including pore size and surface chemistry of the substrate material. This review looks at the applications of mesoporous materials in the confinement of pharmaceutical compounds to increase their dissolution rate or modify their release and the influence of varying pore size to crystallise metastable polymorphs. We focus our attention on mesoporous silicon, due to the ability of its surface to be easily modified, enabling it to be stabilised and functionalised for the loading of various drug compounds. The use of neutron and synchrotron X-ray to examine compounds and the mesoporous materials in which they are confined is also discussed, moving away from the conventional analysis methods.https://www.mdpi.com/1999-4923/12/3/214crystallisationporous silicondrug confinementdrug delivery
collection DOAJ
language English
format Article
sources DOAJ
author Eleanor C. L. Jones
Luis M. Bimbo
spellingShingle Eleanor C. L. Jones
Luis M. Bimbo
Crystallisation Behaviour of Pharmaceutical Compounds Confined within Mesoporous Silicon
Pharmaceutics
crystallisation
porous silicon
drug confinement
drug delivery
author_facet Eleanor C. L. Jones
Luis M. Bimbo
author_sort Eleanor C. L. Jones
title Crystallisation Behaviour of Pharmaceutical Compounds Confined within Mesoporous Silicon
title_short Crystallisation Behaviour of Pharmaceutical Compounds Confined within Mesoporous Silicon
title_full Crystallisation Behaviour of Pharmaceutical Compounds Confined within Mesoporous Silicon
title_fullStr Crystallisation Behaviour of Pharmaceutical Compounds Confined within Mesoporous Silicon
title_full_unstemmed Crystallisation Behaviour of Pharmaceutical Compounds Confined within Mesoporous Silicon
title_sort crystallisation behaviour of pharmaceutical compounds confined within mesoporous silicon
publisher MDPI AG
series Pharmaceutics
issn 1999-4923
publishDate 2020-03-01
description The poor aqueous solubility of new and existing drug compounds represents a significant challenge in pharmaceutical development, with numerous strategies currently being pursued to address this issue. Amorphous solids lack the repeating array of atoms in the structure and present greater free energy than their crystalline counterparts, which in turn enhances the solubility of the compound. The loading of drug compounds into porous materials has been described as a promising approach for the stabilisation of the amorphous state but is dependent on many factors, including pore size and surface chemistry of the substrate material. This review looks at the applications of mesoporous materials in the confinement of pharmaceutical compounds to increase their dissolution rate or modify their release and the influence of varying pore size to crystallise metastable polymorphs. We focus our attention on mesoporous silicon, due to the ability of its surface to be easily modified, enabling it to be stabilised and functionalised for the loading of various drug compounds. The use of neutron and synchrotron X-ray to examine compounds and the mesoporous materials in which they are confined is also discussed, moving away from the conventional analysis methods.
topic crystallisation
porous silicon
drug confinement
drug delivery
url https://www.mdpi.com/1999-4923/12/3/214
work_keys_str_mv AT eleanorcljones crystallisationbehaviourofpharmaceuticalcompoundsconfinedwithinmesoporoussilicon
AT luismbimbo crystallisationbehaviourofpharmaceuticalcompoundsconfinedwithinmesoporoussilicon
_version_ 1724855120981655552